The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Vtorushin S.V.

Siberian State Medical University of the Ministry of Health of Russia;
Cancer Research Institute of the Tomsk National Research Medical Center of the Russian Academy of Sciences

Krakhmal N.V.

Siberian State Medical University of the Ministry of Health of Russia

Zavyalova M.V.

Siberian State Medical University of the Ministry of Health of Russia;
Cancer Research Institute of the Tomsk National Research Medical Center of the Russian Academy of Sciences

Triple-negative breast cancer. Modern molecular genetic concepts and their clinical significance

Authors:

Vtorushin S.V., Krakhmal N.V., Zavyalova M.V.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2021;83(2): 46‑51

DOI: 10.17116/patol20218302146

Read: 5480 times

Contact the author
Table of contents

TRIPLE-NEGATIVE BREAST CANCER. MODERN MOLECULAR GENETIC CONCEPTS AND THEIR CLINICAL SIGNIFICANCE
TRIPLE-NEGATIVE BREAST CANCER. MODERN MOLECULAR GENETIC CONCEPTS AND THEIR CLINICAL SIGNIFICANCE

To cite this article:

Vtorushin SV, Krakhmal NV, Zavyalova MV. Triple-negative breast cancer. Modern molecular genetic concepts and their clinical significance. Russian Journal of Archive of Pathology. 2021;83(2):46‑51. (In Russ.)
https://doi.org/10.17116/patol20218302146

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Prognostic value of mole­cular markers IDO1, DCLK1 and FOXC1 in Triple-negative breast cancer: morphological and clinical correlations. Russian Journal of Archive of Pathology. 2025;(3):88-96
Prognosis of poorly cohe­sive gastric carcinoma depe­nding on the depth of tumor inva­sion and the amount of signet ring cells in tumor. Russian Journal of Archive of Pathology. 2025;(6):20-27
TRPS1 as a novel immu­nohistochemical marker in breast cancer diagnosis. Russian Journal of Archive of Pathology. 2026;(1):80-87
Diagnosis and treatment of ovarian cancer in pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(3):27-33
Hema­tological indi­cators of the systemic inflammatory response in the prognosis of lumi­nal HER2-negative breast cancer patients unde­rgoing surgery followed by adju­vant therapy. P.A. Herzen Journal of Onco­logy. 2025;(3):31-38
Connective tissue defi­ciency in the pathogenesis of ante­rior abdo­minal wall hernias and modern diagnostic approaches to improve hernioplasty outcomes. Russian Journal of Evidence-Based Gastroenterology. 2025;(3):86-94
Endo­thelial factors for prediction of mortality in blood cancer patients with sepsis. Russian Journal of Anesthesiology and Reanimatology. 2025;(5):74-80
Features of postoperative period in late stages of acute abdo­minal diseases. Piro­gov Russian Journal of Surgery. 2025;(11):50-56
Prognosis of recu­rrence in papi­llary thyroid microcarcinoma based on preoperative examination. Piro­gov Russian Journal of Surgery. 2025;(12):23-32
Changes in NT-proBNP and sST2 concentrations after deco­mpensated heart failure and long-term prognosis of patients with CHF and redu­ced LVEF. Russian Cardiology Bulletin. 2025;(4):38-46
Abstract:

Triple negative breast cancer (BC) is a heterogeneous group of carcinomas that substantially differ in clinical, morphological, and molecular genetic characteristics, tumor response to chemotherapy, and prognosis. These features define triple negative BC today as a special clinical problem that has not yet been completely solved. The review is devoted to the description and systematization of the currently available literature data concerning molecular and genetic features and differences in a fairly significant group of breast carcinomas with a severe, aggressive course and an extremely poor prognosis. The review presents the existing molecular genetic classification of triple negative BC based on the results of studies conducted by M.D. Burstein (2015) and B.D. Lehmann (2016), which determines the presence of 4 tumor-specific subtypes: basal-like type (type 1 and type 2), mesenchymal, and luminal androgen receptor types. The paper reflects the main stages of transformation of the proposed classification over the past decade and an attempt has been make to describe the molecular characteristics of each subtype of these carcinomas.

Keywords:

triple negative breast cancer
molecular genetic classification
prognosis

Authors:

Vtorushin S.V.

Siberian State Medical University of the Ministry of Health of Russia;
Cancer Research Institute of the Tomsk National Research Medical Center of the Russian Academy of Sciences

Krakhmal N.V.

Siberian State Medical University of the Ministry of Health of Russia

Zavyalova M.V.

Siberian State Medical University of the Ministry of Health of Russia;
Cancer Research Institute of the Tomsk National Research Medical Center of the Russian Academy of Sciences

Received:

08.12.2020

Accepted:

25.12.2020

Close metadata

References:

  1. Matsumoto H, Koo SL, Dent R, Tan PH, Iqbal J. Role of inflammatory infiltrates in triple negative breast cancer. J Clin Pathol. 2015;68(7):506-510.  https://doi.org/10.1136/jclinpath-2015-202944
  2. Guestini F, McNamara KM, Ishida T, Sasano H. Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification. Expert Opin Ther Targets. 2016;20(6):705-720.  https://doi.org/10.1517/14728222.2016.1125469
  3. Ali AM, Ansari JAK, El-Aziz NMA, Abozeed WN, Warith AMA, Alsaleh K, Nabholtz JM. Triple negative breast cancer: A tale of two decades. Anticancer Agents Med Chem. 2017;17(4):491-499.  https://doi.org/10.2174/1871520616666160725112335
  4. Jia H, Truica CI, Wang B, Wang Y, Ren X, Harvey HA, Song J, Yang JM. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Drug Resist Updat. 2017;32:1-15.  https://doi.org/10.1016/j.drup.2017.07.002
  5. Santonja A, Sánchez-Muñoz A, Lluch A, Chica-Parrado MR, Albanell J, Chacón JI, Antolín S, Jerez JM, de la Haba J, de Luque V, Fernández-De Sousa CE, Vicioso L, Plata Y, et al. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget. 2018;9(41):26406-26416. https://doi.org/10.18632/oncotarget.25413
  6. Nagarajan D, McArdle SEB. Immune landscape of breast cancers. Biomedicines. 2018;6(1):20.  https://doi.org/10.3390/biomedicines6010020
  7. Stovgaard ES, Nielsen D, Hogdall E, Balslev E. Triple negative breast cancer — prognostic role of immune-related factors: a systematic review. Acta Oncol. 2018;57(1):74-82.  https://doi.org/10.1080/0284186X.2017.1400180
  8. Collina F, Aquino G, Brogna M, Cipolletta S, Buonfanti G, De Laurentiis M, Di Bonito M, Cantile M, Botti G. LncRNA HOTAIR up-regulation is strongly related with lymph nodes metastasis and LAR subtype of Triple Negative Breast Cancer. J Cancer. 2019;10(9):2018-2024. https://doi.org/10.7150/jca.29670
  9. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-2767. https://doi.org/10.1172/JCI45014
  10. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC, Mills GB, Lau CC, Brown PH. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688-1698. https://doi.org/10.1158/1078-0432.CCR-14-0432
  11. Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368. https://doi.org/10.1371/journal.pone.0157368
  12. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-5374. https://doi.org/10.1158/1078-0432.CCR-04-0220
  13. Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget. 2015;6(15):12890-12908. https://doi.org/10.18632/oncotarget.3849
  14. Hubalek M, Czech T, Müller H. Biological subtypes of triple-negative breast cancer. Breast Care (Basel). 2017;12(1):8-14.  https://doi.org/10.1159/000455820
  15. Mehanna J, Haddad Fady HD, Eid R, Lambertini M, Kourie HR. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int J Women’s Health. 2019;11:431-437.  https://doi.org/10.2147/IJWH.S178349
  16. Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176-198.  https://doi.org/10.1158/2159-8290.CD-18-1177
  17. Kim S, Moon BI, Lim W, Park S, Cho MS, Sung SH. Feasibility of classification of triple negative breast cancer by immunohistochemical surrogate markers. Clin Breast Cancer. 2018;18(5):1123-1132. https://doi.org/10.1016/j.clbc.2018.03.012
  18. Kim S, Park S, Cho MS, Lim W, Moon BI, Sung SH. Strong correlation of indoleamine 2,3-dioxygenase 1 expression with basal-like phenotype and increased lymphocytic infiltration in triple-negative breast cancer. J Cancer. 2017;8(1):124-130.  https://doi.org/10.7150/jca.17437
  19. Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart M, Rothe F, Sotiriou C. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol. 2018;29(4):895-902.  https://doi.org/10.1093/annonc/mdy024
  20. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68.  https://doi.org/10.1186/bcr2635
  21. Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL, Weinberg RA. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 2017;77(15):3982-3989. https://doi.org/10.1158/0008-5472.CAN-16-3292
  22. Poggi A, Giuliani M. Mesenchymal stromal cells can regulate the immune response in the tumor microenvironment. Vaccines (Basel). 2016;4(4):41.  https://doi.org/10.3390/vaccines4040041
  23. Harano K, Wang Y, Lim B, Seitz RS, Morris SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, Rao AUK, Laere SV, Bertucci F, Woodward WA, Reuben JM, Krishnamurthy S, Ueno NT. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. PLoS One. 2018;13(10): e0204513. https://doi.org/10.1371/journal.pone.0204513
  24. Echavarria I, López-Tarruella S, Picornell A, García-Saenz JÁ, Jerez Y, Hoadley K, Gómez HL, Moreno F, Monte-Millan MD, Márquez-Rodas I, Alvarez E, et al. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to lehmann’s refined classification. Clin Cancer Res. 2018;24(8):1845-1852. https://doi.org/10.1158/1078-0432.CCR-17-1912
  25. Wagenblast E, Soto M, Gutiérrez-Ángel S, Hartl CA, Gable AL, Maceli AR, Erard N, Williams AM, Kim SY, Dickopf S, Harrell JC, Smith AD, Perou CM, Wilkinson JE, Hannon GJ, Knott SR. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature. 2015;520(7547):358-362.  https://doi.org/10.1038/nature14403
  26. Camorani S, Crescenzi E, Gramanzini M, Fedele M, Zannetti A, Cerchia L. Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers. Sci Rep. 2017;7:46659. https://doi.org/10.1038/srep46659
  27. Hill BS, Sarnella A, Capasso D, Comegna D, Del Gatto A, Gramanzini M, Albanese S, Saviano M, Zaccaro L, Zannetti A. Therapeutic potential of a novel αvβ₃ antagonist to hamper the aggressiveness of mesenchymal triple negative breast cancer sub-type. Cancers (Basel). 2019;11(2):139.  https://doi.org/10.3390/cancers11020139
  28. Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol. 2011;24(7):924-931.  https://doi.org/10.1038/modpathol.2011.54
  29. Asghar US, Barr AR, Cutts R, Beaney M, Babina I, Sampath D, Giltnane J, Lacap JA, Crocker L, Young A, Pearson A, Herrera-Abreu MT, Bakal C, Turner NC. Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer. Clin Cancer Res. 2017;23(18):5561-5572. https://doi.org/10.1158/1078-0432.CCR-17-0369
  30. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, Sukumar S, Chang HY. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071-1076. https://doi.org/10.1038/nature08975
  31. Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu KD, Liu YR, Yu Y, Zheng Y, Li X, Zhang C, Hu P, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(3):428-40.e5.  https://doi.org/10.1016/j.ccell.2019.02.001
  32. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19(19):5505-5512. https://doi.org/10.1158/1078-0432.CCR-12-3327
  33. Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O’Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol. 2018;36(9):884-890.  https://doi.org/10.1200/JCO.2016.71.3495
  34. Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014;16(4):406.  https://doi.org/10.1186/s13058-014-0406-x
  35. Millis SZ, Gatalica Z, Winkler J, Vranic S, Kimbrough J, Reddy S, O’Shaughnessy JA. Predictive biomarker profiling of > 6000 breast cancer patients shows heterogeneity in TNBC, with treatment implications. Clin Breast Cancer. 2015;15(6):473-81.e3.  https://doi.org/10.1016/j.clbc.2015.04.008
  36. Rampurwala M, Wisinski KB, O’Regan R. Role of the androgen receptor in triple-negative breast cancer. Clin Adv Hematol Oncol. 2016;14(3):186-193. 
  37. Hon JD, Singh B, Sahin A, Du G, Wang J, Wang VY, Deng FM, Zhang DY, Monaco ME, Lee P. Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res. 2016;6(9):1864-1872.
  38. Z hao S, Ma D, Xiao Y, Li XM, Ma JL, Zhang H, Xu XL, Lv H, Jiang WH, Yang WT, Jiang YZ, Zhang QY, Shao ZM. Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance. Oncologist. 2020;25(10):1481-1491. https://doi.org/10.1634/theoncologist.2019-0982
  39. Babyshkina N, Zavyalova M, Tarabanovskaya N, Dronova T, Krakhmal N, Slonimskaya E, Kzhyshkowska J, Choynzonov E, Cherdyntseva N. Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Mol Cell Biochem. 2018;444(1-2):197-206.  https://doi.org/10.1007/s11010-017-3244-1
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.